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Increased Collagen-linked Pentosidine Levels and Advanced
Glycosylation End Products in Early Diabetic Nephropathy
Paul J. Beisswenger, Lynn L. Moore, Truls Brinck-Johnsen, and Thomas J. Curphey
Departments ofMedicine and Pathology, Dartmouth Medical School, Hanover, New Hampshire 03755;
and the Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756

Abstract
Rationale: Advanced glycosylation end products (AGEs) may
play an important role in the development of diabetic vascular
sequelae. An AGE cross-link, pentosidine, is a sensitive and
specific marker for tissue levels of AGEs.
Objectives: To evaluate the role of AGEs in the development of diabetic nephropathy and retinopathy, we studied pentosidine levels and the clinical characteristics of 48 subjects
with insulin-dependent diabetes mellitus. Diabetic nephropathy was classified as normal, microalbuminuria, or gross proteinuria, and retinopathy was graded as none, background, or
proliferative.
Newly observed findings: Significant elevation of pentosidine (P = 0.025) was found in subjects with microalbuminuria
or gross proteinuria (73.03±9.47 vs 76.46±6.37 pmol/mg col)
when compared with normal (56.96±3.26 pmol/mg col). Multivariate analysis to correct for age, duration of diabetes, and
gender did not modify the results. Elevated pentosidine levels
were also found in those with proliferative when compared with
those with background retinopathy (75.86±5.66 vs 60.42
± 5.98 pmol/mg col) (P < 0.05).
Conclusions: Microalbuminuria is associated with elevated
levels of pentosidine similar to those found in overt diabetic
nephropathy suggesting that elevated AGE levels are already
present during the earliest detectable phase of diabetic nephropathy. (J. Clin. Invest. 1993.92:212-217.) Key words: Maillard
reaction * diabetic retinopathy * diabetic microangiopathy
Amadori reaction * microalbuminuria

Introduction
Increased nonenzymatic glycation of vascular and other tissues
and the accumulation of advanced glycosylation end products
(AGEs)' are felt to play an important role in the development
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of diabetic vascular sequelae (1). The presence of AGEs on
vascular structures is believed to be of particular importance in
the pathogenesis of diabetic microvascular and macrovascular
sequelae. The vascular changes associated with AGE accumulation could play a major role in the development and progression of tissue damage such as end-stage renal disease, retinal
damage, and a host of biochemical and biological abnormalities associated with the accelerated atherosclerotic damage
found in association with long-standing diabetes.
Although there is a substantial body of basic experimental
data that supports the concept that AGEs play an important
role in the development ofdiabetic sequelae, a limited number
of clinical studies have been performed to assess the relationship between tissue levels of AGEs and the development of
diabetic complications (2, 3). The studies conducted to date
have primarily focused on subjects with advanced diabetic sequelae, and detailed examination of renal status and other
characteristics have not been done in these study populations.
Our information on the relationship between the formation
of AGEs in tissues and diabetic vascular sequelae has also been
impeded by the limited number of assays available for the measurement of AGEs. Since many AGEs exhibit natural fluorescence, they have traditionally been measured by fluorimetry at
several distinct excitation and emission wavelengths, although
several new assays have recently been developed. These assays
include one capable of detecting pentosidine, a specific AGE
derived cross-link (4), as well as a radioreceptor/ELISA assay
that can detect a larger family of AGEs (3). These assays are
capable of detecting elevated levels of AGEs in blood or tissues,
but they have not yet been studied for possible relationships
with diabetic vascular sequelae in well-characterized populations of subjects with diabetes.
The goal of the current study is to examine the independent
association between tissue levels of pentosidine and the renal
and retinal sequelae of diabetes by performing a cross-sectional
study of a population with diabetes. To detect larger families of
AGEs, we have also measured these products with more traditional methods that detect fluorescence at 440 nm after excitation at 370 nm (5). Tissue levels of AGEs were studied in
subjects with type I diabetes, who were comprehensively evaluated for diabetic sequelae and other clinical characteristics.

Methods
Subjects. The subjects in this study were selected sequentially from
among the patients regularly attending the Diabetes Clinic at the Dartmouth-Hitchcock Medical Center. To be eligible to participate, subjects must have been 20-55 yr old, have type I diabetes as defined by
the National Diabetes Data Group (6), have normal renal function
based on a serum creatinine within the normal range (53-141 sM or
0.6-1.5 mg/dl), and be willing to undergo a punch biopsy of the skin.
The study, which was approved by the human studies committee, was
explained, and informed consent was obtained.
50 willing and eligible subjects were entered into the study. We were
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unable to obtain an adequate skin biopsy on two of these subjects,
leaving a total of 48 subjects in the current analyses.
We also recruited 29 healthy nondiabetic control subjects between
the ages of 20 and 55 who were willing to undergo a skin biopsy.
Determination of diabetic sequelae. We carried out a complete history and physical examination and evaluated each subject for specific
diabetes-related sequelae. A single retinal specialist (G. F.) examined
each subject by direct and indirect dilated ophthalmoscopy to determine the degree of retinopathy. The specialist classified each subject's
degree of retinopathy as none, background, preproliferative, or proliferative (7). To determine renal function, we collected two 24-h urine
specimens to measure total protein, albumin, and creatinine clearance.
Albumin was determined by RIA using a double antibody method
(Diagnostic Products Corp., Los Angeles, CA), and total protein and
creatinine clearance were determined by the clinical lab at the Dartmouth-Hitchcock Medical Center. Based on 24-h urinary albumin excretion, subjects were classified as normal (< 22 mg/24 h or 15 ,ug/
min), microalbuminuric (22-150 mg/24 h), or as having gross proteinuria (> 150 mg/24 h) (8).
Determination ofadvancedglycosylation endproducts in skin collagen. To determine the level of advanced glycosylation end products in
collagen, a modification of the method of Monnier was used (2). Skin
samples were obtained from the upper right buttock by a 4-mm punch
biopsy and within 30 min, they were snap frozen in liquid nitrogen.
The epidermis was removed by sharp dissection under the dissecting
microscope and after mincing, 4-15 mg of the tissue was further
disrupted with a tissue homogenizer for 60 s (Polytron; Brinkmann
Instruments, Inc., Westbury, NY). The tissue was then delipidated
with chloroform-methanol (2:1 ) for 12 h, washed, and suspended in
0.02 M Hepes buffer (pH = 7.5) containing 0.1 M calcium chloride.
The pellet was then digested in the same buffer containing 280 U of
type VII collagenase (Sigma Immunochemicals, St. Louis, MO) for
48-72 h at 370C with constant shaking. The pellet remaining after
digestion contained < 3% of the total tissue collagen from subjects with
short or long duration diabetes and in those with and without vascular
sequelae. To assay for collagen-linked fluorescence, samples were read
in a spectrofluorimeter (model LS-3B Fluorescence Spectrometer; Perkin-Elmer Corp., Norwalk, CT) at an excitation wavelength of 370 nm
with the reading of emissions at 440 nm (5). All readings were
corrected for an enzyme blank, and hydroxyproline content was determined by the method of Stegemann and Stalder and converted to
collagen assuming a hydroxyproline content of 14% (9). Fluorescence
data are expressed as arbitrary fluorescent units per milligram of collagen. The within assay coefficient of variation (COV) for collagenlinked fluorescence was 6.2%, and the between assay COV was 12%
for autopsy control skin samples from the same subject assayed with
each run.
Determination ofpentosidine levels in skin collagen. For the determination of pentosidine, aliquots ofthe collagenase digests ofskin were
hydrolyzed in 6 N HCl for 24 h at 1 100C in vacuo. Calcium chloride
was removed from the samples by precipitation with oxalic acid, the
calcium oxalate precipitate was washed twice with water, and the supernatant and washes were pooled and taken to dryness using a speedvac system (Savant Instruments, Inc., Farmingdale, NY). The samples
were then made up in mobile phase for the determination of pentosidine.
Pentosidine was determined by HPLC on a chromatograph (model
100A; Beckman Instruments, Inc., Fullerton, CA) using a 25 cm
x 4.6-mm column (Spherisorb 5 ODS 2; Phenomenex Inc., Torrance,
CA) and a mobile phase consisting of 25 mM acetic acid, 25 mM
sodium acetate, 50 mM sodium heptanesulfonate, and .14% (vol/vol)
acetonitrile-water at a flow rate of 1 ml/min. Pentosidine was detected
with a model 1046A fluorescence detector (Hewlett-Packard Co., Palo
Alto, CA) connected to a model 4270 integrator (Spectra-Physics, Eugene, OR) at an excitation wavelength of 330 nm, with the monitoring
of emission at 390 nm.
Quantitation. The amount of pentosidine present was determined
by the external standards method using peak areas. Pentosidine stan-

dards were kindly provided by Dr. Vincent Monnier of Case Western
Reserve University (Cleveland, OH). Standard solutions were prepared by appropriate dilution of a 10-,gM pentosidine standard into
mobile phase buffer. Each standard was injected, as per the samples, at
least three times during the course of a day's run. The areas for the
standards were averaged, a standard curve was constructed, and peak
areas were converted to concentration using a computer program to
perform quadratic interpolation. The COV obtained for the standards
(mean of 10 determinations) were 8% for the 20 nM standard, 4.5% for
the 100 nM standard, and 2.2% for the 300 nM standard.
Statistical methods. The goal of this analysis was to examine the
relationship between tissue levels of AGEs and diabetic renal and retinal sequelae. We examined the tissue levels ofAGEs by fluorescence at
440 nm after excitation at 370 nm and, more specifically, by determining the amount of pentosidine in the tissue. We classified the renal
status of each subject into one of the three categories (normoalbuminuric, microalbuminuric, or gross proteinuric), and then examined the
mean levels of tissue fluorescent products and pentosidine for the subjects in each category. The same univariate analyses were conducted
examining mean tissue levels of AGEs for subjects with the three categories of retinopathy defined previously (none, background, and proliferative).
We used a standard one-way ANOVA to compare mean levels
across groups. The F test from the ANOVA procedure, the ratio of
between-group variability to within-group variability, was used to test
the null hypothesis of no difference in mean AGE or pentosidine levels
among the groups (of diabetic complications). The P value associated
with the overall F tests will be presented in the tables. When a statistically significant difference was found among the groups, a multiple
comparisons procedure, Tukey's test, was used to make two-way comparisons between groups. However, the small numbers of subjects in
some groups, and subsequent low power levels, could preclude firm
conclusions from these post hoc comparisons for some of the subgroups. To adjust for the possible confounding effects of age, gender,
and duration of diabetes, we employed an analysis of covariance to
determine adjusted mean AGE levels for each category of nephropathy
or retinopathy ( 10). Again, we present the P values from the overall F
test from the analysis of covariance.

Results
Characteristics of the total sample. The mean age of the study
population with diabetes was 36.1 yr (range = 21-51 yr) and
that for control subjects was 36.1 yr (range = 20-52 yr). The
mean duration of diabetes was 19.4 yr (range = 4-34 yr) as can
be seen in Table I. 64% of the subjects were male, and 38% and
48% had retinopathy and nephropathy, respectively (Table I).
As can be seen in Table II, the mean levels of albumin excretion for the subgroups with normoalbuminuna, microalbuminuria, and gross proteinuria were 6.33, 42.17, and 373.10
Table I. Characteristics of Total Sample
Mean±SD
Variable

Age (yr)

Controls (no diabetes)

Duration diabetes (yr)

Gender
and sequelae

36.1±8.4

Percent male

64%

Percent with

38%

(21-51)
36.1±8.8
(20-52)
19.4±8.5
(4-34)

of total

retinopathy*
Percent with

48%

nephropathyt

Retinopathy, pre-proliferative or proliferative;
croalbuminuria or gross proteinuria.
*

Proportion

(range)
(n = 48)

*

Nephropathy, mi-
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Table II. Nephropathy Status
Nephropathy
category

Number of

subjects

Albuminuria
Mean±SE

Creatinine clearance
Mean±SE

mg/24 h

mi/s

* Diabetic
A

100

Normoalbuminuria
Microalbuminuria
Gross proteinuria

24
12
12

6.33±0.58
42.17±8.23
373.10±150.7

1.97±0.077
1.83±0.088
1.55±0.079

*

*

41.

Control

ec
0
0O5

&E
mg/24 hr, respectively. When expressed as micrograms per
minute these values were 4.40, 28.0, and 259.1. As also shown
in Table II, the mean values for creatinine clearance in these
three groups were 1.97 ml/s ( 117.9 ml/min) (normoalbuminuria), 1.83 ml/s (109.5 ml/min) (microalbuminuria), and
1.55 ml/s (93.3 ml/min) (gross proteinuria). No significant
relationship was found between creatinine clearance and tissue
levels ofpentosidine when examined by linear regression analysis(P= 0.21).

Pentosidine andAGE levels in diabetic and control subjects.
When tissue levels of pentosidine (mean±SE) were compared
between subjects with and without diabetes (Fig. 1), we found
a statistically significant (P = 0.0001) increase in pentosidine
among subjects with diabetes (diabetes = 66.3±3.6 vs controls
= 31.2±2.2 pmol/mg collagen). We also investigated the relation between age and the tissue levels of pentosidine using linear regression analysis separately for subjects with and without
diabetes (Fig. 2). In the subjects with diabetes, we found that
the tissue levels of pentosidine were higher for any given age
(Fig. 2). In the control subjects, we found a significant positive
relationship between age and tissue levels of pentosidine (P
= .009). Although the P value associated with this relationship
among subjects with diabetes was not as strong (P = .082), the
slope of the regression line (mean±SE) was similar for the two
groups (controls = 0.634±0.226 and diabetes = 0.701±0.395
pmol/yr). Finally, there was a statistically significant linear
relationship between the duration of diabetes and pentosidine
levels (P = 0.016) using a linear regression analysis; higher
pentosidine levels were found in those with longer duration
diabetes (data not shown). This relationship between the duration of diabetes and pentosidine levels was still of borderline
significance (P = 0.054) when adjusted for the confounding
effect of age by multiple regression analysis.
CH)

a

-t

J

41=

_t

E

Q
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o

E
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Figure 2. Changes in pentosidine with age. A significant increase in
pentosidine with age is seen in subjects with type 1 diabetes (open
diamonds) and nondiabetic controls (solid triangles). As can be seen
by the slopes of the regression lines (controls = 0.634 ± 0.226 and
diabetic = 0.701 ± 0.395), the rate of increase with age is similar in
both groups.

Pentosidine and AGE levels in subjects with diabetic nephropathy. When the relation between the degree of nephropathy and tissue levels of pentosidine was examined using ANOVA techniques (Table III), we found a statistically significant
difference in pentosidine levels (mean±SD) among subjects
with normal albumin excretion (56.6±16.3 pmol/mg collagen), microalbuminuria (72.1±30.1 pmol/mg collagen), and
gross proteinuria (79.2±21.5 pmol/mg collagen). The P value
from the overall F test examining differences across the three
groups was 0.013. It is interesting to note that pentosidine levels were very similar for subjects with microalbuminuria and

Table III. Mean Levels ofAdvanced Glycosylation End Products
by Category of Diabetic Complication
Diabtic complication

Pentosidine
Mean±SD

370/440 nm
Mean±SD

pmol/mg collagen

FU/mg collagen

56.6±16.3

8.9±2.9
12.8±4.2
13.1±3.5
0.001

-

66.34-3.6
(n0

fis

Control

Figure 1. Pentosidine
levels in subjects with
and without diabetes.
Significant differences
were found for pentosidine levels in subjects
with type 1 diabetes (n
= 48) and controls (n
= 29).

Renal status (n = 47)
Normoalbuminuria (n = 23)
Microalbuminuria (n = 12)
Gross proteinuria (n = 12)
P valuet
Retinal Status (n = 48)
Normal (n = 13)
Background (n = 20)*
Proliferative (n = 15)
P value

72.1±30.1
79.2±21.5
0.013
59.8± 15.6
62.9±24.7
77.9±24.5
0.076

9.7±2.9
10.0±3.6
12.9±4.6
0.049

Background retinopathy category includes three subjects with preproliferative retinopathy.
* P value from overall F test from ANOVA. (Null hypothesis: no difference among group means).
*
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gross proteinuria. Based on the multiple comparisons procedure (Tukey's test), the pentosidine levels for both those with
microalbuminuria and gross proteinuria differed significantly
from those found in subjects with normoalbuminuria (Table
III); the difference between the microalbuminuric and gross
proteinuric groups was not, however, statistically significant.
When tissue levels of AGEs measured by fluorescence at excitation/emission wavelengths of 370/440 nm were investigated
using the F test derived from ANOVA (Table III), similar differences (P value = 0.001 ) were seen overall between subjects
with normal albumin excretion (8.9±2.9 fluorescent units
(FU)/mg collagen) and those with either microalbuminuria or
gross proteinuria ( 12.8±4.2 and 13.1±3.5 FEU/mg collagen respectively). As was seen with pentosidine, the levels of AGEs
measured by fluorescence were similar in subjects with microalbuminuria and gross proteinuria, while both groups differed significantly from those with normal albumin excretion
when examined by the multiple comparisons procedure.

Pentosidine and AGE levels in subjects with diabetic retinopathy. The relationship between the retinopathy category
and the tissue levels of pentosidine and fluorescent AGEs can
be seen as well in Table III. Those with more advanced degrees
of retinopathy (proliferative) had higher levels of pentosidine
(77.9±24.5 pmol/mg collagen) than those with either no detectable retinal change or background retinopathy (59.8 and
62.9 pmol/mg collagen, respectively), although these differences (P = 0.076) did not quite achieve significance at the P
< 0.05 level. Similar findings were seen when tissue levels of
AGEs were measured as fluorescent products at excitation/
emission wavelengths of 370/440 nm (no retinopathy, 9.7;
background retinopathy, 10.0; and proliferative retinopathy,
12.9 FU/mg collagen), although the difference across categories did achieve significance (P = 0.049). Pentosidine levels
and fluorescent AGE levels were similar for subjects with no
retinopathy and those with background retinopathy (P > 0.05)
when examined by a multiple comparisons procedure (Tukey's test).
Pentosidine and AGE levels adjusted for age, duration of
diabetes, and gender. In Table IV, we present the results of the
analysis of covariance used to adjust for potential confounding
by age, gender, and duration of diabetes. As can be seen in this
table, the adjusted mean levels of pentosidine and fluorescent
AGEs (measured at excitation/emission wavelengths of 370/
440 nm) were similar in each category of nephropathy and
retinopathy to the unadjusted levels, indicating little or no confounding by any of the three potential confounding factors.
When adjusted pentosidine or fluorescent AGE levels were examined across the three categories of nephropathy, significant
differences were found among those with normoalbuminuria,
microalbuminuria, and gross proteinuria when examined by
the Ftest across groups (P = 0.010 and 0.0008 ) for pentosidine
and fluorescent AGEs, respectively.
After adjusting for age, duration of diabetes, and gender,
the relations between pentosidine and retinopathy (P
= 0.065), as well as fluorescent AGEs and retinopathy (P
= 0.041), were similar to the earlier unadjusted results, although the P value for the difference in pentosidine levels
across retinopathy categories was again found to be of borderline significance. Using the adjusted data, those with either no
retinopathy or with background retinopathy had lower pentosidine and fluorescent AGE values than those with proliferative

retinopathy.

Table IV. Adjusted* Levels of Advanced Glycosylation End
Products by Category of Diabetic Complication
Diabetic sequelae

Renal Function (n = 47)
Normoalbuminuria (n = 23)
Microalbuminuria (n = 12)
Gross proteinuria (n = 12)
P valuet
Retinal status (n = 48)
Normal (n = 13)
Background (n = 20)
Proliferative(n= 15)
P valuet

Pentosidine
Mean±SD

370/440 nm
Mean±SD

pmoilmg collagen

FU/mg collagen

57.4±22.5
68.6±21.5
81.4±23.3
0.010

9.1±3.6
12.3±3.4
13.1±3.7
0.0008

68.1±30.4
60.5±23.3
73.8±24.5
0.065

10.1±5.1
10.1±3.9
12.5±4.1
0.041

All mean levels were adjusted for age, gender, and duration of diabetes using an analysis of covariance procedure.
* P value from overall F test from ANOVA. Null hypothesis: no difference among group means, after adjustment for age, gender, and
diabetes duration.)
*

Discussion
Analysis of the levels of pentosidine and fluorescent advanced
glycosylation end-products in our subjects with and without
diabetes showed that diabetes is associated with a significant
elevation of these products in skin collagen. A significant increase in pentosidine was also found with increasing age, as
well as with increasing duration of diabetes. The relationship
between pentosidine and age was highly significant for nondiabetic subjects but of borderline significance for those with diabetes. This may be secondary to the greater variability in pentosidine levels in those with diabetes which, in turn, could be
related to the heterogeneity in the diabetic population regarding duration of diabetes and the level of vascular sequelae. Although the absolute levels of pentosidine were significantly increased in diabetes, the rate of increase in pentosidine with
increasing age, as reflected in the slopes, was similar for those
with and without diabetes (Fig. 2). This conflicts with the findings of an earlier study by Monnier et al. in which they found
an accelerated rate of increase in tissue fluorescence with increasing age for those with diabetes relative to control subjects
( 11). The current study is, however, in agreement with a recently published study by Sell and Monnier, which also found
that the rate of increase in pentosidine with age was similar for
diabetic and control subjects ( 12). These studies suggest that
increased tissue levels of pentosidine occurs fairly early in the
diabetic syndrome, although studies of greater numbers diabetic subjects with short duration diabetes will be necessary to
document the point at which this increase occurs.
The tissue levels of pentosidine and fluorescent AGEs were
also found to be significantly elevated in subjects with diabetic
nephropathy. However, when the relationship between retinopathy and AGEs was examined, the elevation of pentosidine and
fluorescent AGE levels in those with proliferative retinopathy
was marginally significant relative to those who had minimal
or no evidence of significant retinal sequelae (Table III). The
elevated levels of AGEs (and pentosidine) persisted after adjustment for differences in age, duration of diabetes, and
Increased Pentosidine Levels in Early Diabetic Nephropathy
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gender by multivariate analysis (Table IV), suggesting that the
relationships between the diabetes-related complications and
tissue levels of AGEs or pentosidine are not significantly confounded by these factors. In addition to finding elevated levels
of pentosidine and AGEs in the tissues of those with overt
diabetic nephropathy, we also found that subjects with microalbuminuria had elevated pentosidine and fluorescent product levels relative to those with normal albumin excretion (Tables III and IV). Conversely, levels of pentosidine and fluorescent AGEs in microalbuminuric subjects were similar to those
seen in subjects with clinically more advanced degrees of diabetic nephropathy (gross proteinuria). Finding elevated levels
of pentosidine and fluorescent AGEs in subjects with microalbuminuria, which is generally considered an earlier and potentially reversible phase of diabetic nephropathy (8, 13), suggests
that generalized modification of tissue collagen may already be
present during this phase of diabetic nephropathy. The finding
of significant elevation of AGEs during the microalbuminuria
phase of diabetic nephropathy also supports the findings of
Chavers et al. which showed that significant changes in glomerular morphology were already present during this stage of nephropathy ( 14). In the current study, we purposely defined
microalbuminuria using the most conservative criteria for abnormal albumin excretion to avoid selection of those with
more advanced glomerulosclerosis ( 15 ). In spite of this selection process, elevated AGE levels were found in the group with
microalbuminuria, as well as in those with more advanced degrees of proteinuria. It should also be noted, however, that
collagen in vascular structures is presumably the site of pathology in diabetes, and that although skin collagen is similar to
other collagens in its slow turnover ( 16), it is possible that
tissue remodeling and receptor-mediated turnover processes
may differ in different collagen containing tissues.
Our finding that significant elevation of pentosidine and
fluorescent AGEs is associated with diabetic nephropathy does
not agree with the data of Sell and Monnier. Although one
study by the same authors showed significant elevation of tissue levels of pentosidine in association with end-stage renal
disease in diabetic and nondiabetic subjects ( 17), other studies
showed no significant relationship between diabetic nephropathy and tissue levels of fluorescent AGEs (2), or pentosidine in
the absence of end-stage renal disease ( 12). In the later studies,
the failure to demonstrate elevated AGEs in association with
nephropathy may be partially caused by the method that they
used to classify nephropathy. In these studies, they defined
stage 0 nephropathy as urinary protein excretion of less than
500 mg/24 h, which if classified by currently accepted methods, would include subjects with microalbuminuria and more
advanced proteinuria (8, 15). In the current study, we have
shown that tissue levels of pentosidine and fluorescent AGEs
are significantly elevated in association with microalbuminuria
and gross proteinuria (defined as 24-h urinary protein excretion of 22-150 mg/24 h or > 150 mg/24 h, respectively). Because of the wide range of proteinuria in their 0 nephropathy
group, it is quite likely that Sell et al. could have included a
number subjects with significant albuminuria in this group,
and this could spuriously increase AGE levels in the group that
they defined as having minimal nephropathy. This could mask
differences in tissue levels of AGEs between this group and
those with greater degrees of proteinuria, and preclude finding
a significant relationship between pentosidine or fluorescent
AGEs and diabetic nephropathy.
216
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When the relationship between diabetic retinopathy and
the tissue levels of pentosidine and fluorescent AGEs was examined (Tables III and IV), we found thnt AGE levels in those
with less advanced diabetic retinopathy (background) are similar to the levels seen in those with normal retinal exams, and
that AGE levels in both of these subgroups are lower than those
with more advanced grades of retinopathy (proliferative).
Since the relationship between pentosidine and the degree of
retinopathy was of borderline significance, and we were unable
to demonstrate differences in the groups with no retinopathy
and background retinopathy, our results suggest that elevated
tissue levels of AGEs are less predictive of the earlier stages of
retinopathy then for the earlier microalbuminuria stage ofdiabetic nephropathy. When the data were adjusted for age, duration of diabetes, and gender, the tissue levels of pentosidine
were slightly lower in the group with background retinopathy
than in those with no detectable retinopathy (Table IV), although these differences did not approach statistical significance. The moderately large variability around the mean pentosidine levels (as can be seen from the standard deviations
presented in Table IV) and the relatively small sample sizes in
some groups could account for this unexpected finding. Thus,
it would be beneficial to examine larger numbers of subject
with each type of complication in future studies (particularly
with retinal complications) to derive more stable estimates of
adjusted mean pentosidine levels. It is also possible that more
sensitive methods for classifying diabetes-related retinal damage may be necessary to demonstrate significant differences in
AGE levels between groups with earlier stages of retinopathy.
Tissue levels of other specific AGEs or families of AGEs ( 1820) may also be more predictive of diabetes-associated retinopathic changes than pentosidine or AGEs measured by fluorescence.
In our study, as in previous studies (21 ), we found an increased risk of multiple diabetes-related complications in cer-

tain individuals; 12 ofthe 15 subjects with proliferative retinopathy also had evidence of diabetic nephropathy (eight with
gross proteinuria and four with microalbuminuria). It is possible that this association of retinopathy with nephropathy and
the significant relationship between nephropathy and tissue levels of AGEs could result in nephropathy having a confounding
effect on the relationship between retinopathy and AGEs, although it is difficult to determine the importance ofthis association because of the small numbers of subjects with advanced
retinopathy without concurrent nephropathy.
Although we found a definite association between AGE levels and the presence of diabetic renal sequelae and a possible
association of AGEs and diabetic retinopathy in this cross-sectional study, this association does not prove that AGEs play a
causal role in the development of vascular complications.
There exists, however, a large body of data to support an important role for AGEs in the pathogenesis of diabetes-related
vascular damage. Previous studies have demonstrated that the
accumulation of these products on collagens and other proteins
can produce structural and functional changes in vascular tissues by multiple mechanisms. Increased cross-linking of structural proteins such as collagens and basement membranes can
lead to decreased compliance and rates of turnover of structural components of the vascular wall and can also lead to
functional abnormalities, such as abnormal basement membrane filtration function (22). Abnormal autoaggregation of
basement membrane collagenous subunits (23, 24), abnormal
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association of type IV collagen with other basement membrane
components such as laminin, proteoglycans and intactin (25),
as well as increased immunogenicity (26) and succeptibility to
macrophage-induced damage (27) can all occur as a result of
tissue modification by AGEs. AGE accumulation on, or in
proximity to cellular components ofthe vascular wall, can also
result in direct cytotoxicity or indirect macrophage/cytokine
induced damage (27). AGE-associated modification of structural proteins in the capillary or arterial wall and dysfunction
or death of cellular elements could lead to stiff, less compliant
vessels with altered permeability and other functional characteristics and eventually, luminal occlusion from excessive accumulation of basement membrane material or basement
membrane-protein adducts. These changes could play a major
role in the development and progression of the tissue damage
such as end-stage renal disease, retinal damage, and the host of
biochemical and biological abnormalities associated with the
accelerated atherosclerotic damage found in association with

long-standing diabetes.
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